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 Background: Mycophenolic acid (MPA) prodrugs are anti-proliferative immunosuppressive agents commonly used after or-
gan transplantation. Although they are generally well tolerated by patients, adverse effects may occur. It is pos-
tulated that MPA metabolites could also contribute to these adverse effects.
 Material/Methods: The objective of this study was the assessment of concentrations of total MPA and its metabolites, phenyl gluc-
uronide (MPAG), acyl glucuronide (AcMPAG) and glucoside (GluMPA), using liquid chromatography combined 
with mass spectrometry (LC/MS/MS) in two groups: kidney transplant recipients and liver transplant patients. 
Associations of MPA and its metabolites with adverse effects were analyzed.
 Results: The study group consisted of 211 recipients of liver or kidney transplants who received immunosuppressive 
therapy, including MPA prodrugs. Multivariant analysis showed a positive influence of MPA on gastroentero-
toxicity in kidney transplant recipients. In liver patients, gastroenterotoxicity was associated with lower MPAG 
concentrations. A positive influence of AcMPAG on bacterial infections in liver transplant patients was observed. 
In liver transplant recipients, a positive influence of MPA and a negative influence of GluMPA levels on the PLT 
count were revealed. MPA and its metabolites did not influence the hemoglobin levels in both groups. There 
were no significant relationships among MPA, its metabolites and WBC counts.
 Conclusions: In kidney transplant recipients, total MPA trough concentration is associated with gastroenterotoxicity and its 
monitoring could have important role in management of gastrointestinal complications. The quantification of 
AcMPAG in liver recipients receiving MPA may be helpful in avoiding bacterial infections. GluMPA seems to 
have a toxic effect on thrombopoiesis.
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Background
Mycophenolic acid (MPA) is widely used for the treatment of 
patients undergoing solid organ transplantation as part of a 
multiple drug regimen, usually with concomitant cyclosporine 
or tacrolimus and corticosteroids to prevent graft rejection. 
MPA blocks the conversion of inosine monophosphate by ino-
sine monophosphate dehydrogenase (IMPDH), a key enzyme 
in the de novo purine biosynthetic pathway [1]. Although my-
cophenolic acid pro-drugs, including mycophenolate mofetil 
(MMF) and mycophenolate sodium (MPS), are generally well-
tolerated in patients, such adverse effects as: infections, leu-
copoenia, anemia, and gastrointestinal problems may occur, 
necessitating dose reduction or discontinuation and thereby 
potentially jeopardizing patient and graft outcomes. Dose re-
duction and discontinuation of MPA therapy have been asso-
ciated with an increased risk of acute rejection episodes and 
kidney graft loss [2].
In contrast to other immunosuppressants, mycophenolate 
mofetil and mycophenolate sodium preparations were intro-
duced for clinical use without a recommendation of thera-
peutic drug monitoring (TDM). Clinical experience has shown 
that it is possible and, in some cases, necessary to use vari-
ous methods of TDM, such as the assessment of the area un-
der the concentration-time curve (AUC) and minimum plasma 
drug concentration (through concentration). These evaluations 
have shown high inter- and intra-individual variability in the 
MPA exposure parameters. Although several MPA metabolites 
have been identified, their assessment is not used routinely. 
The major MPA metabolite is phenolic glucuronide (MPAG), 
and other minor metabolites include 7-O-glucoside (GluMPA) 
and acyl-glucuronide (AcMPAG) [3,4]. Whereas MPAG is inac-
tive, AcMPAG is capable of inhibiting human IMPDH in vitro 
and has been considered toxic [4,5]. There is scarce informa-
tion regarding GluMPA levels and actions in solid organ trans-
plant (SOT) patients.
The aim of the study was to assess the levels of the total MPA 
and of its three metabolites, MPAG, AcMPAG, and GluMPA, us-
ing liquid chromatography combined with tandem mass spec-
trometry (LC/MS/MS) in SOT recipients. We hypothesized that 
metabolites of MPA could affect the occurrence of the adverse 
effects of the drug.
Material and Methods
This study involved the participation of 211 solid organ trans-
plant recipients. All of the patients under the care of our trans-
plant center were eligible for inclusion. All consecutive outpa-
tients who gave their written informed consent to participate in 
the study were included. All blood samples were taken during 
routine blood tests on outpatient visits to the Transplant and 
Nephrology Clinic between November 2011 and July 2012. 
Blood was taken just before the administration of the morn-
ing dose of MPA, between 8.30 and 9.00 am (trough concen-
tration) and after fasting for at least 8 hours. Blood was col-
lected in EDTA tubes and placed at +4°C, then centrifuged to 
obtain plasma. Plasma was stored at –80°C until the time of 
determination of MPA and its metabolites concentrations by 
LC/MS/MS method. Blood sampling was accompanied by the 
collection of relevant laboratory and clinical data.
Renal function was assessed with the use of estimated glo-
merular filtration rate (eGFR) by Modification of Diet in Renal 
Disease (MDRD) [6]. MPA dosage: To standardize the data on 
daily mycophenolate mofetil and mycophenolate sodium dos-
age (MPAcd), mycophenolate sodium doses were converted to 
equivalent mycophenolate mofetil doses (MPAcd=MPS [mg/day] 
×1.3889). Gastroenterotoxicity in patients was assessed based 
on patients’ medical history. Symptoms, including diarrhea, ab-
dominal pain, and vomiting, especially recurrent vomiting, were 
identified. We excluded other causes of these problems, such 
as CMV infection or other infections on the basis of fever inci-
dence; elevated C-reactive protein levels; or positive CMV DNA 
PCR. According to the clinical symptoms, the patients were di-
vided into two groups: those with gastroenterotoxicity (recur-
rent or few episodes of diarrhea, abdominal pain or vomiting, 
not related to infection, with the resolution of the symptoms 
following MPA dose reduction) and those without gastroen-
terotoxicity (no typical symptoms or symptoms related to in-
fection). The incidence of infections was based on the pres-
ence of suggestive clinical characteristics and was confirmed 
by microbiologic studies of representative biological samples 
and agreeable results from additional tests, including elevated 
CRP, procalcitonin, and white blood cell counts. CMV infection 
was diagnosed on the basis of typical clinical symptoms and 
positive CMV DNA PCR results. Anemia was diagnosed if the 
blood hemoglobin was <120 g/L (women) or <130 g/L (men).
Chemicals. The chemicals used included the following: LC-MS 
grade – methanol, 25% ammonium hydroxide and formic acid 
(J.T. Baker), and analytical grade - ammonium acetate (POCh, 
Gliwice, Poland). Ultra-pure water was obtained from a wa-
ter purification system (Mili-Q, Millipore, Milford, MA, USA). 
MPA, deuterated MPA (MPA-d3), AcMPAG, MPAG, and GluMPA 
(Toronto Research Chemicals Inc., North York, Canada) were a 
gift from Roche Poland. Stock solutions were prepared in meth-
anol and stored at –20°C. As an internal standard for MPA and 
all metabolites, MPA-d3 was applied.
Sample preparation. MPA and all metabolites were quanti-
fied in the blood plasma. The whole blood samples were cen-
trifuged (10 min at 1000 RCF) to obtain the plasma. Sample 
preparation was performed as follows: 100 μL of plasma was 
2
Zegarska J. et al.: 
Blood concentrations of mycophenolic acid and its metabolites affect…
© Ann Transplant, 2015; 20:
ORIGINAL PAPER
Indexed in: [Science Citation Index Expanded] [Index Medicus/MEDLINE] 
[Chemical Abstracts] [Scopus]
PR
O
O
F 
©
 IN
TE
RN
AT
IO
N
AL
 S
CI
EN
TI
FI
C 
IN
FO
RM
AT
IO
N
1
5
10
15
20
25
30
35
40
45
50
53
1
5
10
15
20
25
30
35
40
45
50
53
transferred into a 1.5-mL silanized conical test tube (Sigma 
Aldrich), and then 250 μL of methanol (with MPA-d3) was add-
ed for protein precipitation and analyte extraction. After the 
mixture was vortexed (1 min) and centrifuged (2 min at 18626 
RCF), the entire supernatant was transferred to the vial and 
analyzed by LC/MS/MS.
Instrumentation. The instrumentation consisted of a Waters 
Acquity Ultra Performance Liquid Chromatograph coupled with 
a Waters TQ-S triple-quadruple mass spectrometer. For the in-
strument control and data acquisition, MassLynx software was 
used. LC/MS/MS analysis was performed in the positive elec-
trospray ionization mode (ESI). The mass spectrometer was 
operated in a multiple-reaction monitoring (MRM) mode. The 
concentration of each analyte was calculated per MPA-d3.
Analyses
For chromatographic separation, we applied the UPLC BEH 
Phenyl column (50×2.1 mm, 1.7 μm, Waters), thermostated at 
45°C. Mobile phase A consisted of 300 μL of formic acid and 
900 μL of 25% NH4OH in 1000 mL of water, and mobile phase 
B consisted exclusively of methanol. The flow rate of the mo-
bile phase was set at 0.5 mL/min, and the injection volume was 
10 μL for the analysis of MPA, GluMPA and AcMPAG and 2 μL 
for the analysis of MPAG. The gradient scheme was 3% B ini-
tially, followed by an increase to 90% B at 2.0 min. At 2.3 min, 
the mobile phase reverted to the initial conditions (3% B). The 
total analysis time was 3 min, including re-equilibration time. 
For all of the analyzed compounds, the mass spectrometer 
optimized settings were as follows: capillary voltage=2.5 kV, 
desolvation temperature=200°C, desolvation gas flow=800 L/h, 
cone gas flow=150 L/h, nebulizer gas pressure=7.0 bar, source 
temperature=150°C. The MRM transitions, cone voltages, colli-
sion energies and retention times used in the described meth-
ods are presented in Table 1. The first MRM transition of each 
compound served as a quantitative transition; the second, as 
a confirmation transition. To define the relationship between 
the concentration and detector responses of analytes, 6-level 
calibrators were prepared for each MPA metabolite, as well as 
for the parent compound. The concentrations of the calibrators 
covered entire ranges of the expected (determined empirically 
based on several patients’ samples prior to the validation pro-
cess) concentrations in the patients’ samples (1–7 μg/ml for 
MPA, 0.01–1 μg/ml for MPA glucoside, 0.5–5 μg/ml for AcMPAG 
and 10–200 μg/ml for MPAG). The mean R2 coefficients of the 
calibration curves for all compounds from 7 sample batches 
were not lower than 0.97. The imprecision level of the method 
was assessed using 120 in-house control samples and was de-
termined by measuring 4 sets of 10 samples at three concen-
tration levels within the ranges of expected concentration in 
the patient. Imprecision values for all compounds were deter-
mined at the following four concentration levels, expressed as a 
coefficient of variation (CV): <6% for MPA, <12.3% for GluMPA, 
<11.4% for AcMPAG and up to 26% for MPAG. The mean recov-
ery for all of the analytes was as follows: 93.9% for MPA, 88.3% 
for GluMPA, 92.2% for AcMPAG and 93% for MPAG.
Statistics
The analyzed database comprised 249 medical records for 211 
patients. The data were weighted according to the number of 
Immunosuppressive agent MRM transition Cone voltage Collision energy
Retention 
time [min]
Mycophenolic acid (MPA)
338.16>207.10 (qt) 10 15 1.81
338.16>275.19 10 15
MPA glucoside
500.21>303.02 (qt) 15 20 1.50
500.21>275.10 15 25
500.21>207.12 15 30
MPA acyl glucuronide
514.19>207.12 (qt) 15 35 1.64
514.19>303.02 15 20
514.19>321.10 15 10
MPA phenyl glucuronide
514.19>321.10 (qt) 15 10 1.33
514.19>303.02 15 20
514.19>207.12 15 35
MPA-d3 341.22>210.04 10 25 1.80
Table 1.  Monitored transitions, cone voltages, collision energies, and retention times of the analyzed compounds.
qt – quantification transition; MPA – mycophenolic acid; MPA-d3 – deuterated mycophenolic acid; MRM – multiple-reaction monitoring 
(MRM) mode.
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records for each patient, such that each unit observation rep-
resents one patient. The analyses were corrected by using 
the Bonferroni correction. Normality was estimated with the 
Kolmogorov-Smirnov test. Unless specified otherwise, contin-
uous data are described as means ±SD for a normal distribu-
tion, or as medians and ranges for data with any non-normal 
distribution. The differences between the normally distributed 
variables were assessed with Student’s t test; in other cases, 
the Mann-Whitney U test was applied. Correlations between 
the parameters were calculated with the Spearman correla-
tion coefficient for all non-normally distributed values. Then, 
we used the multivariate analysis methods and a number of 
regression models were constructed to control for the effects 
of patients’ sex, age, eGFR level and transplant organ on the 
Characteristic Ktx (n=162) Ltx (n=49)
Age [years]  47.95 (12.1)  50.83 (12.73)
Sex (Female)  67 (41.36%)  23 (46.94%)
BMI [kg/m2]  25.49 (3.99)  25.75 (3.98)
eGFR MDRD [ml/min/1.73 m2]  44.9 (18.18)  59.14 (24/36)
Hb [g/dL]  13.16 (1.97)  13.02 (2.14)
WBC [G/L]  7.81 (2.63)  6.45 (2.39)
PLT [G/L]  223 (72–449)  177 (9–705)
AlAT [U/L]  24 (8–294)  41 (8–185)
MPA [μg/mL]  2.28 (0.31–19.82)  1.06 (0.14–5.4)
GluMPA [μg/mL]  0.07 (0.004–0.96)  0.03 (0.0–0.24)
AcMPAG [μg/mL]  0.77 (0.15–7.14)  0.45 (0.14–2.84)
MPAG [μg/mL]  70.3 (0.66–409.71)  31.44 (1.43–168.77)
MPA corrected dose [mg/day]  1500 (500–2500)  1000 (500–2000)
Time from TX [months]  58 (1–294)  38 (1–154)
GS+Tac+MPA  60 (37.04%)  21 (42.86%)
GS+CsA+MPA  55 (33.95%)  4 (8.16%)
Tac+MPA  18 (11.11%)  12 (24.49%)
CsA+MPA  13 (8.03%)  8 (16.33%)
GS+MPA  11 (6.79%)  3 (6.12%)
GS+SIR+MPA  3 (1.85%) –
MPA  1 (0.62%)  1 (2.04%)
EVE+MPA  1 (0.62%) –
Gastroenterotoxicity  27 (16.67%)  8 (16.33%)
Infectious complications  73 (45.06%)  17 (34.7%)
Bacterial infections  56 (34.57%)  11 (22.45%)
Viral infections  31 (19.14%)  8 (16.33%)
Table 2.  Demographic, clinical, and laboratory characteristics of the study groups: kidney (n=162) and liver transplant recipients 
(n=49).
BMI – body mass index; TX – type of transplantation; Ktx – kidney transplantation; Ltx – liver transplantation; 
eGFR MDRD – estimated glomerular filtration rate calculated by Modification of Diet in Renal Disease equation; AlAT – alanine 
aminotransferase; MPA – mycophenolic acid; GluMPA – MPA glucoside; AcMPAG – MPA acyl-glucuronide; MPAG – MPA phenolic 
glucuronide; GS – glucocorticosteroids; CsA – cyclosporine; Tac – tacrolimus; SIR – sirolimus; EVE – everolimus; CMV – cytomegalovirus; 
WBC – white blood cell count; RBC – red blood cell count; Hb – hemoglobin; PLT – blood platelet count.
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concentrations of MPA or its metabolites. Other medical fac-
tors, including hemoglobin, red blood cell count (RBC), platelet 
count (PLT), white blood cell count (WBC), infection and gas-
troenterotoxicity, were also analyzed. In the latter two cases, 
in which the dependent variables were binary, logistic regres-
sion models were applied; linear regression was used in all 
other cases. A p-value of <0.05 was considered to be signifi-
cant. All statistical analyses were performed using IBM SPSS 
Statistics software version 19.0 for Windows.
Results
Patients’ demographics and concentrations of MPA, MPAG, 
AcMPAG and GluMPA are shown in Table 2. Chromatograms 
for all compounds in this method are presented in Figure 1.
In the kidney transplant recipients (Ktx) in the group with gas-
troenterotoxicity (GT) MPA concentrations were higher in com-
parison with the group without GT (Table 3). There were no 
significant differences in the MPAG, AcMPAG or GluMPA con-
centrations between the group with GT and the group with 
no gastroenterotoxicity in Ktx group (Table 3). Multivariant 
analysis using logistic regression using gastroenterotoxici-
ty as a dependent variable confirmed that in kidney recipi-
ents MPA concentrations were associated with GT, indepen-
dent of the patient’s sex, age, eGFR, MPA corrected dosage, 
and metabolite concentrations (Table 4). In liver transplant 
recipients (Ltx) in the group with GT, there were significantly 
MPAG concentrations in comparison with the group with no 
GT (Table 3). However, there was no difference between those 
groups in MPA concentrations. Logistic regression in liver pa-
tients confirmed negative influence of MPAG concentrations 
on gastrointestinal adverse effects (Table 4).
Ktx patients with bacterial infections or all types of infections 
had higher MPAG concentrations in comparison with the group 
without infections (Table 3). However, logistic regression, in-
cluding the patients’ sex, age, eGFR level, MPA dosage and 
metabolite concentrations as controlled variables, revealed 
no significant relationships among MPA, MPAG, AcMPAG and 
GluMPA and infectious complications (all types of infections, 
bacterial and viral infections) in this population (Table 4). In 
liver transplant recipients there was no difference between 
group with and without infections in MPA or metabolite con-
centrations (Table 3). However, multivariant analysis showed 
the positive influence of AcMPAG on bacterial infections in liv-
er transplant patients (Table 4).
In kidney transplant recipients MPAG and GluMPA was signifi-
cantly negatively correlated with hemoglobin (Table 5). Based 
on the linear regression, MPA or its metabolites did not in-
fluence hemoglobin concentration in both Ktx and Ltx pa-
tients (Table 4).
Univariate analysis and linear regression using PLT count as 
a dependent variable revealed no significant relationships 
among MPA, MPAG, AcMPAG and GluMPAG and PLT counts in 
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Figure 1.  Chromatograms of mycophenolic acid and its derivatives: acyl glucuronide, glucoside, and phenyl glucuronide.
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Ktx group (Tables 4, 5). MPAG concentrations were significant-
ly positively correlated with PLT count in Ltx group (Table 5). In 
the group of liver transplant recipients, we observed a statis-
tically significant positive influence of MPA and a negative in-
fluence of GluMPA levels on PLT count after adjusting for pa-
tient sex, age, eGFR, AlAT, MPAG, and MPA corrected dosage 
(Table 4). In kidney and liver transplant recipients there were 
no associations between MPA and its metabolites and WBC 
count both in univariate and multivariate analyses (Tables 4, 5).
Discussion
Here, we have presented an analysis of levels of MPA and its 
three metabolites in group of MPA-treated transplant recipi-
ents. We have used our novel LC-MS/MS method allowing for 
the complete separation of MPA and its derivatives. We tried 
to link MPA and its metabolites to side effects in two differ-
ent groups: kidney and liver graft recipients.
Our analysis revealed higher concentrations of MPA in kidney 
transplant recipients with gastroenterotoxicity. The relationship 
Ktx (n=162) Ltx (n=49)
Yes No p Yes No p
GT
MPA
3.4
(0.99–12.47)
2.19
(0.31–19.82)
0.003*
1.23
(0.14–3.06)
1.02
(0.15–5.41)
0.99
GluMPA
0.07
(0.01–0.96)
0.07
(0.004–0.77)
0.12
0.02
(0.0–0.06)
0.04
(0.003–0.24)
0.15
AcMPAG
1.05
(0.41–2.41)
0.72
(0.15–7.14)
0.13 (0.36–0.14)
0.48
(0.14–2.84)
0.13
MPAG
77.83
(24.89–158.29)
66.86
(0.66–409.71)
0.39
21.74
(1.43–31.44)
39.14
(2.38–168.77)
0.016*
Viral 
infections
MPA
2.28
(0.31–19.82)
2.42
(0.73–16.71)
0.61
1.12
(0.18–3.44)
1.06
(0.14–5.41)
0.99
GluMPA
0.06
(0.004–0.77)
0.08
(0.01–0.96)
0.33
0.04
(0.003–0.08)
0.02
(0.0–0.24)
0.59
AcMPAG
0.77
(0.15–7.14)
0.94
(0.22–3.95)
0.48
0.55
(0.18–1.2)
0.44
(0.14–2.84)
0.41
MPAG
69.0
(0.66–409.71)
83.58
(17.0–222.24)
0.4
33.55
(3.45–47.23)
31.44
(1.43–168.77)
0.56
Bacterial 
infections
MPA
2.28
(0.85–7.85)
2.27
(0.31–19.82)
0.64
1.05
(0.15–5.41)
1.1
(0.14–4.36)
0.56
GluMPA
0.07
(0.01–0.96)
0.07
(0.004–0.77)
0.23
0.04
(0.003–0.1)
0.03
(0.0–0.24)
0.9
AcMPAG
0.91
(0.17–3.04)
0.72
(0.15–7.14)
0.12
0.61
(0.14–2.84)
0.44
(0.14–2.79)
0.45
MPAG
85.48
(1.0–409.71)
60.86
(0.66–314.31)
0.01*
27.87
(3.45–132.5)
31.52
(1.43–168.77)
0.91
All infections 
MPA
2.28
(0.73–16.71)
2.3
(0.31–19.82)
0.87
1.05
(0.15–5.41)
1.01
(0.14–4.36)
0.73
GluMPA
0.07
(0.01–0.96)
0.06
(0.004–0.77)
0.13
0.04
(0.003–0.1)
0.03
(0.0–0.24)
0.98
AcMPAG
0.9
(0.17–3.95)
0.72
(0.15–7.14)
0.08
0.46
(0.14–2.84)
0.44
(0.14–2.79)
0.59
MPAG
83.58
(1.0–409.71)
57.93
(0.66–314.31)
0.017*
29.36
(3.45–132.92)
31.52
(1.43–168.77)
0.78
Table 3.  Comparison of concentrations of MPA and its metabolites in patients with and without adverse effects in the 2 groups: kidney 
and liver transplant recipients.
GT – gastroenterotoxicity; Ktx: kidney transplantation; Ltx: liver transplantation; MPA: mycophenolic acid; GluMPA: MPA glucoside; 
AcMPAG: MPA acyl-glucuronide; MPAG: MPA phenolic glucuronide; * p<0.05.
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between high MPA trough concentrations and adverse drug 
effects has been reported by several investigators. In a study 
of 22 kidney transplant recipients, the MPA trough concen-
tration was significantly higher in patients with episodes of 
diarrhea, infection or hematological adverse effects than in 
those without such events; these findings are in agreement 
with the results of the our study [7]. However, other studies 
have revealed contradictory results in this respect. There was 
no association between the incidence of GT symptoms and 
thrombocytopenia and the total and free MPA pharmacokinet-
ic parameters in the group of pediatric kidney transplant re-
cipients [8]. In a prospective, randomized, double-blind, multi-
center and controlled study of 150 renal transplant recipients, 
a dose-dependent increase in the adverse effects of kidney re-
cipients was observed in the first 6 months following trans-
plantation. However, no relationship between MPA trough con-
centrations or AUCs and adverse effects was detected [9]. In a 
retrospective study, 4 of 27 kidney transplant recipients with 
Independent variable Dependent variable
Ktx (n=162) Ltx (n=49)
B p B p
MPA
Gastroenterotoxicity
0.260 0.04* 8.130 0.07
MPAG –0.005 0.421 –0.330 0.04*
AcMPAG –0.626 0.126 –0.738 0.605
GluMPA 0.967 0.625 –57.113 0.147
MPA
Viral infections
0.160 0.060 –0.012 0.976
MPAG 0.000 0.957 –0.054 0.096
AcMPAG –0.031 0.909 –0.591 0.584
GluMPA 2.158 0.269 3.986 0.846
MPA
Bacterial infections
–0.224 0.093 –0.531 0.370
MPAG 0.004 0.322 0.023 0.158
AcMPAG 0.156 0.469 2.040 0.05*
GluMPA 2.229 0.254 7.063 0.705
MPA
All types of infections
–0.02 0.76 –0.01 0.97
MPAG 0.004 0.28 0.003 0.88
AcMPAG 0.19 0.38 0.83 0.27
GluMPA 1.6 0.38 –0.81 0.96
b p b p
MPA
Hemoglobin
–0.081 0.350 –0.063 0.804
MPAG –0.134 0.115 –0.453 0.075
AcMPAG 0.129 0.108 –0.193 0.356
GluMPA 0.071 0.398 –0.072 0.801
MPA
PLT
0.098 0.343 0.650 0.004*
MPAG 0.068 0.499 –0.001 0.997
AcMPAG –0.110 0.244 0.330 0.087
GluMPA 0.009 0.928 –0.520 0.042*
MPA
WBC
–0.055 0.522 –0.083 0.638
MPAG 0.047 0.644 –0.104 0.696
AcMPAG –0.078 0.419 0.128 0.551
GluMPA 0.164 0.101 0.092 0.750
Table 4.  Relationship between MPA and its metabolites and their therapeutic complications in the 2 groups: kidney and liver 
transplant recipients (multivariate analyses results).
Ktx – kidney transplantation; Ltx – liver transplantation; MPA – mycophenolic acid; GluMPA – MPA glucoside; AcMPAG – MPA acyl-
glucuronide; MPAG – MPA phenolic glucuronide; WBC – white blood cell count; PLT – platelet count; * p<0.05.
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gastrointestinal adverse effects had significantly lower MPA 
AUC values. It was suggested that, in patients with gastroin-
testinal toxicity, drug absorption is decreased, leading to fur-
ther local irritation [10].
Some authors have postulated the involvement of AcMPAG in 
causing gastrointestinal disturbances among patients treated 
with mycophenolate mofetil or sodium [11]. We did not ob-
serve such associations in kidney recipients. Other studies were 
also unable to confirm the relationship between MPA metab-
olites and GT: Grinyo et al. did not find correlations between 
MPA, AcMPAG exposure or maximal concentration (C max) of 
AcMPAG and the occurrence of gastrointestinal symptoms af-
ter 7 days and after 1 month in their pharmacokinetic study of 
82 renal transplant recipients [12]. Heller et al. were not able 
to find any relationship between AcMPAG concentrations and 
the incidence of diarrhea in renal transplant recipients [13].
Little is known about MPA metabolites and their associations 
with gastrointestinal problems in liver transplant recipients. 
We have found a negative influence of MPAG levels on gastro-
enterotoxicity in liver transplant recipients. The clinical signif-
icance of this finding remains unclear. It cannot be excluded 
that lower MPAG levels are the consequence of decreased en-
terohepatic circulation in the course of diarrhea. Interestingly, 
MPA concentrations were not related to gastrointestinal symp-
toms in this group. In a study of 67 liver transplant patients 
the occurrence of diarrhea was not related to pharmacokinet-
ics of MPA and its metabolites [14].
There are few reports available on the impact of the concen-
trations of MPA and its metabolites on the incidence of infec-
tious complications in SOT patients. It has been proposed that 
AcMPAG may contribute to side effects of the MPA formulations, 
which include myelotoxicity, infections and gastroenterotoxic-
ity [15]. Those toxic effects may be mediated by interleukin-6 
and tumor necrosis factor alpha induced by AcMPAG in human 
mononuclear leukocytes [11]. Interestingly, it has been demon-
strated that some of the effects of AcMPAG are independent 
of the major mechanism of MPA action, which is associated 
with inosine monophosphate dehydrogenase inhibition [16]. 
It has been speculated that AcMPAG could exert an antipro-
liferative effect and inhibit proliferation of human mononu-
clear leukocytes via a mechanism independent of guanosine 
triphosphate (GTP) depletion [15]. Other studies have shown 
contradictory results regarding the influence of MPA levels on 
infectious complications. The mean MPA through concentra-
tions were higher in 13 patients with adverse effects, main-
ly infectious, compared with those without adverse effects in 
a retrospective study of 30 renal transplant recipients [17]. 
On the other hand, in a retrospective study of 21 renal trans-
plant patients over the first 28 days following transplantation, 
no differences in the drug dosage or MPA AUC were detect-
ed between recipients with and without viral infections [18]. 
Some authors reported relationship between high free MPA-
AUC and MPA-Cmax levels and infections [8]. The authors did 
not observe such a relationship when the total MPA pharma-
cokinetic parameters were analyzed.
Ktx (n=162) Ltx (n=49)
r p r p
Hb
MPA –0.001 0.99 0.21 0.16
GluMPA –0.19 0.015* 0.09 0.54
AcMPAG –0.02 0.8 0.03 0.86
MPAG –0.28 0.0003* –0.09 0.55
Plt
MPA 0.05 0.54 0.24 0.09
GluMPA 0.06 0.43 0.25 0.09
AcMPAG –0.02 0.77 0.15 0.3
MPAG 0.07 0.4 0.32 0.02*
WBC
MPA –0.01 0.92 0.09 0.54
GluMPA 0.05 0.57 0.06 0.67
AcMPAG 0.02 0.8 0.05 0.72
MPAG 0.11 0.15 0.004 0.98
Table 5.  Correlations of MPA and its metabolites concentrations with hemoglobin concentration, blood platelets count, and white 
blood cells count in the 2 groups: kidney and liver transplant recipients.
Ktx – kidney transplantation; Ltx – liver transplantation; MPA – mycophenolic acid; GluMPA – MPA glucoside; AcMPAG – MPA acyl-
glucuronide; MPAG – MPA phenolic glucuronide; Plt – blood platalets; Hb – hemoglobin; WBC – white blood cells; * p<0.05.
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In our study in kidney transplant recipients neither MPA nor 
its metabolites influenced bacterial or viral infections’ occur-
rence. However, in liver transplant recipients unfavorable in-
fluence of AcMPAG on bacterial infections’ incidence was ob-
served. We have not found any reports concerning relationship 
among MPA, its metabolites and infection episodes in Ltx pa-
tients. This finding seems to be interesting and suggests the 
need of further research on this topic.
In multivariate analyses we did not confirmed negative cor-
relations of GluMPA and MPAG concentrations and hemoglo-
bin levels in Ktx patients. However, other authors observed a 
negative influence of MPA, MPAG and AcMPAG on erythropoi-
esis. In a prospective study of 100 renal transplant patients, 
those with anemia and leucopenia had significantly higher MPA 
AUC12 than those with normal RBC and WBC [19]. A prospec-
tive multicenter study of 33 kidney transplant patients demon-
strated a relationship of high MPAG and AcMPAG levels with 
leucopenia and anemia [20]. In the group of 106 renal trans-
plant recipients, the MPAG pharmacokinetic parameters cor-
related negatively with hemoglobin and hematocrit [21]. The 
authors of this paper concluded that MPAG might be a pre-
dicting factor for the side effects of mycophenolates. Ting et 
al. reported that anemia, leucopenia, infection and rejection 
occurred in lung and heart transplant recipients with higher 
AcMPAG AUC [22]. Inconclusive results of the research to date 
suggest that also in this field there is a need of analyses of 
larger patients’ groups. In liver transplant recipients we did 
not observe the influence of MPA metabolites on hemoglobin 
levels. We did not also find any reports on this issue in the lit-
erature. We hope to obtain more conclusive results from anal-
yses of larger group, which is currently recruited by our team.
In kidney transplant recipients we found no associations be-
tween MPA or its metabolites and thrombocytopenia. It is con-
sistent with observations made by other investigators. Weber 
et al. did not observe any associations between free or total 
MPA pharmacokinetic parameters and thrombocytopenia in 
kidney transplant recipients [8]. In liver transplant patients 
GluMPA was associated with thrombocytopenia, suggesting 
a disadvantageous effect of GluMPA on thrombocytopoiesis 
in the bone marrow. Additionally, higher MPA levels were as-
sociated with higher Plt count, which was confirmed by multi-
variate analyses. The significance of this finding remains elu-
sive and needs further investigation.
The relationship between MPA levels and gastrointestinal 
symptoms, observed in kidney transplant patients, was not 
confirmed in the liver transplant group, possibly because the 
number of patients in this group was too small. The fact that 
the association between MPA metabolites and other adverse 
effects occurred only in liver transplant recipients is interest-
ing. We hypothesized that it might be caused by lower eGFR 
values in the Ktx group in comparison with liver transplant re-
cipients. It could result in increased accumulation of MPA me-
tabolites and cause attenuation of interplay between them and 
the analyzed complications.
The present study has some limitations, including its obser-
vational nature and limitation to a single center. The lack of 
exclusion criteria reflects the natural characteristics of this 
patient population after solid organ transplantation. The het-
erogeneity of the group is also left open to being influenced by 
confounding factors, such as various lengths of time elapsed 
since transplantation, 2 different MPA prodrugs, and different 
immunosuppression regimens. It has been proved that there 
are some differences between MMF and MPS preparations in 
terms of maximal concentration and AUC profiles, but their 
impact on IMPDH activity is not well defined [23,24]. In pedi-
atric liver transplant patients there was no statistically signif-
icant difference between formulations of MPA in the gene ex-
pression of IMPDH 2, in the AUC(0-12h), or in C max, but peak 
concentration occurred later with MPS [25]. Parallel analysis 
of the concentrations of MPA and its metabolites in patients 
after Ktx and Ltx allowed a unique comparison of differences 
in their impact on adverse reactions occurrence between kid-
ney and liver transplant recipients.
Conclusions
In conclusion, there are differences in the relationship between 
concentrations of MPA or its metabolites and adverse effects 
in kidney graft recipients and liver graft recipients. Those dif-
ferences only partially could be explained. Precise measure-
ments of the total MPA trough concentrations seem to be im-
portant in kidney recipients to monitor adverse gastrointestinal 
effects. On the other hand, the quantification of AcMPAG con-
centrations in liver transplant recipients receiving immunosup-
pressive therapy with MPA may be helpful in avoiding bacte-
rial infections. Additionally, GluMPA, of unknown significance 
so far, seems to have a toxic effect on thrombopoiesis in this 
group. The assessment of the GluMPA concentrations could 
help to prevent thrombocytopenia. Further studies are need-
ed to verify if monitoring of MPA and its metabolites would be 
beneficial for the long-term management of patients receiv-
ing mycophenolate formulations. The quantification of MPA 
metabolites could then be an important part of therapeutic 
monitoring and may be helpful in establishing safer immuno-
suppressive therapies.
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